Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
StemGen, Human SCF, Human SCF-Amgen
Synonyms :
ancestim
Class :
Protein-based therapy& hemopoietic growth factors
Dosage Forms & Strengths
Powder for injection
1875mcg/vial
Mobilization of PBPC (peripheral blood progenitor cells)
In combination with filgrastim,
20mcg/kg, subcutaneous injection, once a day
Autologous Peripheral Blood Progenitor Cell MobilizationÂ
In combination with filgrastim, 20mcg/kg, subcutaneous injection, once a day :
1875
mcg/vial
Powder for injection
Injection
once a day
Autologous Peripheral Blood Progenitor Cell MobilizationÂ
In combination with filgrastim, 20 mcg/kg, subcutaneous injection, once a day :
1875
mcg/vial
Powder for injection
Injection
once a day
Dosage Forms & Strengths
Safety study not established
Refer to adult dosing
levobupivacaine has the potential to lower the rate of excretion of ancestim, potentially leading to elevated levels of serum
excretory rate of ancestim may be reduced with aclidinium, resulting in higher levels in serum
excretory rate of ancestim may be increased with acetazolamide, which results in lower levels in serum
the excretory rate of ancestim may be reduced with aceclofenac, which results in higher levels in serum
The excretory rate of ancestim may be reduced with pyridoxine, which results in higher levels in serum
The excretory rate of ancestim may be reduced with rasagiline, which results in higher levels in serum
the rate of excretion of streptomycin may be decreased when taken with ancestim
The excretory rate of ancestim may be reduced with sulindac, resulting in higher levels in serum
The excretory rate of ancestim may be reduced with tinidazole, which results in higher levels in serum
The excretory rate of ancestim may be reduced with trimethoprim, resulting in higher levels of serum
coadministration of ancestim with vincristine might increase the risk of peripheral neuropathy
cefpirome leads to a reduction in the rate of excretion of ancestim which leads to increased level of serum
ancestim leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
ancestim leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
ancestim leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
morniflumate may decrease the excretion rate of ancestim, resulting in a potential increase in serum levels
ancestim may decrease the excretion rate of almasilate, leading to higher serum levels
the rate of excretion of aurothioglucose may be reduced with ancestim
the rate of excretion of ancestim may be reduced
the rate of excretion of ancestim may be reduced
Actions and spectrum:
ancestim is known to act on progenitor cells of hematopoietic stem cells that stimulate functional activation, proliferation, differentiation, and commitment. This results in a rise in the number of PBPC(peripheral blood progenitor cells), such as erythroid burst-forming units, granulocyte macrophage colony-forming units, and CD34.
Frequency not defined
Nausea
Tachycardia
Headache
Dizziness
Reaction at the site of injection
Tingling sensation
Numbness
Black Box Warning
For subcutaneous(SC) use only
Not for intravenous(IV) administration
Contraindication/Caution:
Contraindication:
Allergy to ancestim or the proteins of Escherichia coli
Caution:
Patients need to be observed for an hour after administration of ancestim
Dosage should not be exceeded
Pregnancy consideration:
US FDA pregnancy category: No sufficient data
Lactation:
Data not available
Pregnancy category:
Category A:Â Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C:Â there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D:Â adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N:Â There is no data available for the drug under this category
Pharmacology:
Pharmacodynamics:
Hematopoietic progenitor cells ancestry influences their commitment, differentiation, multiplication, and functional activation. Increases in spreading peripheral blood progenitor cells such as CD34, erythroid burst-forming units and granulocyte-macrophage colony-forming units, are the outcome of this stimulation.
Pharmacokinetics:
Absorption
Bioavailability of more than 60% is noticed with ancestim in preclinical study. Peak plasma concentration of 3.6-13.7ng/ml is attained 15-24 hours after administration of 5-25mcg/kg dose of ancestim.
Distribution
ancestim is known to be distributed mainly in the plasma and kidney as reported in preclinical study
Metabolism
Ancestim is degraded into low molecular weight products
Elimination and excretion
90% of ancestim is known to be eliminated through urine in preclinical study
Half-life:
2-5hours
Administration:
Ancestim is administered as a subcutaneous injection along with filgrastim
Reconstitute with 1.2 ml of sterile water for injection to obtain a concentration of 1.5mg/ml
Patient information leaflet
Generic Name: ancestim
Why do we use ancestim?
ancestim (StemGen) is used to enhance the mobilization of hematopoietic stem cells and the number of PBPC. It is administered along with filgrastim.